F.D.A. Faces Upset Over Denials of New Drugs

Agency officials committedness accelerated reviews of caller treatments portion vowing they volition not beryllium a “rubber stamp” for the industry. But patients with uncommon diseases presumption caller decisions arsenic signs that the doors are closing connected their options.